<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Definitive surgical management of renal cell carcinoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Definitive surgical management of renal cell carcinoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Definitive surgical management of renal cell carcinoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal cell carcinoma (RCC) is responsible for 80 to 85 percent of all primary renal neoplasms. Over 81,800 people are diagnosed with RCC on an annual basis in the United States, with almost 15,000 deaths expected each year [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For patients with localized RCC and select patients with advanced RCC, surgery can be curative. This topic will review the role of surgery in the definitive management of RCC.
        </p>
        <p>
         Related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3001.html" rel="external">
          "Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">
          "Diagnostic approach, differential diagnosis, and management of a small renal mass"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for definitive surgery for RCC are based on disease stage  (
         <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">
          table 1
         </a>
         ) and the extent of disease  (
         <a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">
          algorithm 1
         </a>
         ). Appropriate candidates include patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I or II RCC (disease limited to the kidney).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III RCC, which includes patients with tumor extension into major veins or perinephric tissues and/or enlarged retroperitoneal lymph nodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of the inferior vena cava and/or the cardiac atrium (ie, cavoatrial tumor involvement). (See
         <a class="local">
          'Cavoatrial tumor involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RCC with direct extension into the ipsilateral adrenal gland (a subset of stage IV RCC), especially if there is no other evidence of metastatic disease. (See
         <a class="local">
          'Adrenal gland involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The role of cytoreductive nephrectomy in other patients with stage IV RCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          OVERVIEW OF THE SURGICAL APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H163821258">
         <span class="h2">
          Radical versus partial nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing definitive surgical treatment for RCC, a radical or partial nephrectomy may be performed. Our approach is as follows [
         <a href="#rid2">
          2
         </a>
         ]  (
         <a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H1195271237">
         <span class="h3">
          Radical nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer a radical nephrectomy in patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors &gt;10 cm in size.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors involving a more central position of the kidney.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors with increased oncologic potential as evidenced by:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suspected lymph node involvement (see
         <a class="local">
          'Retroperitoneal lymph nodes'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumor with associated renal vein or inferior vena cava thrombus (see
         <a class="local">
          'Cavoatrial tumor involvement'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Direct extension into the ipsilateral adrenal gland (see
         <a class="local">
          'Adrenal gland involvement'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3058263111">
         <span class="h3">
          Partial nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer a partial nephrectomy in order to preserve renal function in patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor ≤10 cm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A partial nephrectomy is technically feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbidities that are likely to impact renal functions in the future (see
         <a class="local">
          'Indications for nephron-preserving surgery'
         </a>
         below):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A solitary kidney (see
         <a class="local">
          'Solitary kidney'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple, small, and/or bilateral tumors (see
         <a class="local">
          'Multiple or bilateral tumors'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with or at risk for chronic renal disease (see
         <a class="local">
          'Baseline renal dysfunction'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Our approach is consistent with the guidelines of the American Urological Association (AUA) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In the randomized trial EORTC 30904, 541 patients with clinical stage T1 or T2 RCC were randomly assigned to partial or radical nephrectomy [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There were 12 local or regional recurrences in 268 patients managed with partial nephrectomy (4.5 percent) compared with 9 of 273 (3 percent) in those managed with radical nephrectomy. The number of patients who developed distant metastases was low in both groups (7 and 6 patients, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The 10-year overall survival rate was lower with partial nephrectomy (76 versus 81 percent, hazard ratio (HR) 1.50, 95% CI 1.03-2.16), but only 12 of the 117 deaths in the entire study population were due to RCC. The cancer-specific survival rate was not statistically different (HR 2.06, 95% CI 0.62-6.18).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After a median follow-up of 6.7 years, fewer patients developed moderate renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;60) after partial nephrectomy (65 versus 86 percent), while the incidence of advanced kidney disease (eGFR &lt;30) was relatively similar (6 versus 10 percent) between partial and radical nephrectomy, and the incidence of kidney failure (eGFR &lt;15) was nearly identical (1.6 versus 1.5 percent) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A 2016 meta-analysis of 107 studies with a majority of T1 renal masses compared partial and radical nephrectomy with a median follow-up of 60 months [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cancer-specific survival rates were not different between radical and partial nephrectomy, but both decreased with tumor stage (97 versus 98.8 percent for T1a, 91 versus 90 percent for T1b, 82.5 versus 86.7 percent for T2 tumors).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial nephrectomy was associated with a smaller decline in postoperative glomerular filtration rate (weighted mean difference -3.6, 95% CI -4.1 to -3.2) than radical nephrectomy, and a lower incidence of chronic kidney disease (CKD) stage 3 or above (risk ratio 0.39, 95% CI 0.30 to 0.51).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial nephrectomy was associated with more blood transfusions and urological complications than radical nephrectomy, but the overall complication rates were similar.
        </p>
        <p>
        </p>
        <p>
         Similarly, a 2023 meta-analysis of 31 studies associated partial nephrectomy with a decreased risk of postoperative early-stage CKD and cardiovascular events compared with radical nephrectomy. However, no benefit of was observed in advanced CKD, new-onset or worsening hypertension, myocardial infarction, and cardiovascular mortality [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4106054865">
         <span class="h2">
          Open versus minimally invasive approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         A radical nephrectomy can be performed as an open surgical procedure or laparoscopically/robotically. The choice of surgical technique should be based on patient-specific considerations (eg, tumor location and size) and the technical expertise available. In most institutions, laparoscopic nephrectomy has replaced open radical nephrectomy for many patients, especially if the tumor size is less than 10 cm. According to a large United States database study, the percentage of radical nephrectomies performed robotically increased from 1.5 percent in 2003 to 27 percent in 2015 [
         <a href="#rid7">
          7
         </a>
         ]. In randomized trials, laparoscopic radical nephrectomy led to less postoperative pain and a faster return to normal activities than open nephrectomy [
         <a href="#rid8">
          8
         </a>
         ]. Long-term oncological outcomes after laparoscopic radical nephrectomy for RCC are excellent and appear comparable to those of open surgery [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         As with radical nephrectomy, both open and laparoscopic/robotic partial nephrectomy techniques are utilized and result in comparable outcomes [
         <a href="#rid11">
          11,12
         </a>
         ]. Although laparoscopic partial nephrectomy is technically difficult, robotic-assisted, laparoscopic partial nephrectomy has evolved as a technique that offers similar outcomes to open partial nephrectomy yet has the advantage of precision and maneuverability to minimize ischemia times [
         <a href="#rid13">
          13,14
         </a>
         ]. In several meta-analyses of robotic versus open partial nephrectomy, robotic partial nephrectomy had a longer operative time, but less blood loss, shorter length of stay, and fewer complications [
         <a href="#rid15">
          15,16
         </a>
         ]. In a meta-analysis of comparative nonrandomized studies, although robotic assistance does not appear to offer any incremental benefit over conventional laparoscopic surgery in radical nephrectomy [
         <a href="#rid17">
          17,18
         </a>
         ], such benefit does exist in partial nephrectomy [
         <a href="#rid19">
          19
         </a>
         ]. Nevertheless, there are still some challenging partial nephrectomies that are safer done open rather than minimally invasively.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          RADICAL NEPHRECTOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with RCC limited to the kidney, a radical nephrectomy results in a five-year cancer-specific survival rate between 80 and 90 percent [
         <a href="#rid3">
          3,9,20,21
         </a>
         ]. However, patients are at risk for long-term renal dysfunction as a result of the procedure, with the reported risk exceeding 30 percent [
         <a href="#rid22">
          22-24
         </a>
         ]. Hospitals and surgeons doing a higher volume of nephrectomies have lower mortality compared with those institutions with lower volumes [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H472954975">
         <span class="h2">
          Techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radical nephrectomy consists of ligation of the renal artery and vein and removal of the kidney, Gerota fascia, and, on occasion, the ipsilateral adrenal gland. However, in the absence of high risk of local invasion of the adrenal gland, resection of the adrenal gland should be omitted because the incidence of adrenal metastases is uncommon (10 percent or less) in clinically localized RCC [
         <a href="#rid27">
          27-29
         </a>
         ]. (See
         <a class="local">
          'Adrenal gland involvement'
         </a>
         below.)
        </p>
        <p>
         Early ligation of the vascular pedicle is important to prevent tumor dissemination at surgery [
         <a href="#rid30">
          30
         </a>
         ]. Of the various open approaches described (eg, thoracoabdominal, extrapleural, and anterior transabdominal), we prefer the anterior transabdominal approach because it offers the ability to remove the tumor through a relatively small incision. However, with large upper-pole tumors, the thoracoabdominal incision may be preferable, allowing palpation of the ipsilateral lung cavity and mediastinum. In addition, this allows the exposure required to resect a pulmonary metastasis if it is identified intraoperatively [
         <a href="#rid31">
          31
         </a>
         ]. Minimally invasive approaches are discussed elsewhere. (See
         <a class="local">
          'Open versus minimally invasive approaches'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4012616165">
         <span class="h2">
          Retroperitoneal lymph nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymph node dissection need not be performed routinely in patients with localized kidney cancer and clinically negative nodes [
         <a href="#rid2">
          2
         </a>
         ]. Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform an extended lymphadenectomy for patients deemed to be at an increased risk for lymph node involvement (eg, tumor grade 3 or 4, sarcomatoid histology, T3 or T4 tumor, presence of coagulative necrosis) and in patients with suspected nodal metastases on preoperative imaging [
         <a href="#rid32">
          32,33
         </a>
         ]. Lymph nodes from the ipsilateral great vessel and the interaortocaval region should be removed from the crus of the diaphragm to the common iliac artery [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with no preoperative evidence of abdominal node involvement and not at an increased risk of nodal metastases, we typically perform a limited lymphadenectomy which removes the lymph nodes in the renal hilum, as there is no apparent therapeutic benefit to a more extended lymphadenectomy.
        </p>
        <p>
        </p>
        <p>
         The only data from a randomized trial, from the European Organization for Research and Treatment of Cancer (EORTC) 30881 trial, evaluated 772 patients who were assigned to radical nephrectomy alone or radical nephrectomy with lymph node dissection [
         <a href="#rid35">
          35
         </a>
         ]. At a median follow-up of over 12 years, there were no differences in overall survival or deaths due to cancer in the two treatment arms. However, only 4 percent of patients in this study had pathologically involved lymph nodes, limiting the generalizability of these results [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Large retrospective series have not been able to confirm a survival benefit for lymph node dissection among patients undergoing radical nephrectomy for nonmetastatic RCC [
         <a href="#rid37">
          37-39
         </a>
         ]. Thus, lymph node dissection for RCC is primarily for staging and prognostic purposes. Patients with lymph node involvement confirmed on final pathology may be eligible for adjuvant therapy. (See
         <a class="local">
          'Adjuvant therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2638908109">
         <span class="h2">
          Cavoatrial tumor involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         RCC is complicated by cavoatrial tumor involvement in about 10 percent of cases [
         <a href="#rid40">
          40
         </a>
         ]. For patients with evidence of thrombus involving the inferior vena cava (IVC) and/or right atrium (ie, cavoatrial involvement) but without evidence of distant or nodal metastases, we proceed with thrombectomy at the time of radical nephrectomy [
         <a href="#rid41">
          41
         </a>
         ]. In such patients, thrombectomy can provide immediate palliation of symptoms with five-year survival rates up to 70 percent [
         <a href="#rid42">
          42,43
         </a>
         ]. Patients with a lower tumor thrombus level (I/II) and those with a lower body mass index have better survival after thrombectomy [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The extent of thrombectomy depends on the extent of involvement of the tumor [
         <a href="#rid44">
          44
         </a>
         ]. Four stages of cavoatrial tumor involvement have been described  (
         <a class="graphic graphic_figure graphicRef78193" href="/z/d/graphic/78193.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Level I
         </strong>
         – Thrombus &lt;2 cm above the renal vein
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Level II
         </strong>
         – Thrombus below the intrahepatic vena cava
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Level III
         </strong>
         – Thrombus involves the intrahepatic vena cava but is below the diaphragm
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Level IV
         </strong>
         – Thrombus involves the atrium
        </p>
        <p>
        </p>
        <p>
         For patients with thrombus extending up to the major hepatic veins, a simple thrombectomy may suffice [
         <a href="#rid45">
          45
         </a>
         ]. For patients whose thrombus extends above the major hepatic veins, cardiopulmonary bypass with or without hypothermic circulatory arrest may be required to achieve a complete resection.
        </p>
        <p>
         However, postoperative morbidity and mortality can be significant [
         <a href="#rid46">
          46
         </a>
         ], including the rare complication of intraoperative tumor embolization [
         <a href="#rid47">
          47
         </a>
         ]. Although no perioperative strategies are warranted to prevent embolization, patients who had an embolic event preoperatively should be treated with heparin. IVC filters are generally avoided as they need to be placed above the renal veins, and if they become blocked, they can impair function of the remaining kidney.
        </p>
        <p class="headingAnchor" id="H1389529223">
         <span class="h2">
          Adrenal gland involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with solitary ipsilateral adrenal metastases identified by preoperative imaging studies, we proceed with adrenalectomy at the time of nephrectomy. This approach is supported by a series of 648 patients who underwent radical nephrectomy combined with adrenalectomy over a 20-year period [
         <a href="#rid48">
          48
         </a>
         ]. In this series, 48 patients (7 percent) had adrenal metastases, of which 13 were solitary adrenal metastases without other evidence of systemic disease. Median overall survival for patients without any metastatic disease was 13.8 years; for those with isolated solitary adrenal metastases without other systemic spread, median survival was 11.7 years. In contrast, median survival for those with lymph node metastases or distant metastases was approximately one year.
        </p>
        <p>
         In addition, an adrenalectomy may be performed in patients who may be at risk for direct extension into the adrenal gland, including patients with upper-pole lesions &gt;4 cm or upper-pole non-organ-confined tumor (T3 or greater). However, the benefit of adrenalectomy in this setting is less clear-cut [
         <a href="#rid49">
          49
         </a>
         ]. Adrenalectomy should not be performed if the contralateral adrenal gland is absent and the ipsilateral gland demonstrates normal morphology and no malignant involvement [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2585099226">
         <span class="h2">
          Large, marginally resectable tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a large tumor deemed to be only marginally resectable, preoperative renal arterial embolization may be an option to reduce vascularity and lower the risk of intraoperative hemorrhage at the time of planned nephrectomy [
         <a href="#rid50">
          50
         </a>
         ]. However, the limited data has not associated it with either a survival benefit or a technical benefit compared with patients who proceed with nephrectomy alone [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H387391471">
         <span class="h1">
          PARTIAL NEPHRECTOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with tumors ≤10 cm and those at risk for a significant loss of renal function should be managed with a partial nephrectomy if it is technically feasible. As noted above, partial nephrectomy results in similar oncologic outcomes compared with radical nephrectomy in appropriately selected patients. In addition, it is associated with a significantly lower risk of chronic renal dysfunction [
         <a href="#rid3">
          3,53,54
         </a>
         ]. (See
         <a class="local">
          'Radical versus partial nephrectomy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3962502768">
         <span class="h2">
          Indications for nephron-preserving surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Absolute indications for nephron-preserving approach such as partial nephrectomy include solitary kidney, bilateral tumors, or known familial RCC [
         <a href="#rid2">
          2
         </a>
         ]. Relative indications include patients with baseline kidney dysfunction (eg, chronic kidney disease [CKD] or proteinuria).
        </p>
        <p class="headingAnchor" id="H2271267926">
         <span class="h3">
          Solitary kidney
         </span>
         <span class="headingEndMark">
          —
         </span>
         For RCC in a patient with a solitary kidney, we recommend a partial nephrectomy whenever possible. In a series of over 1000 renal mass in solitary kidney, over 80 percent underwent partial nephrectomy [
         <a href="#rid55">
          55
         </a>
         ]. As only 25 to 30 percent of a solitary kidney needs to be preserved to avoid renal replacement therapy, partial nephrectomy is feasible for most patients with a solitary kidney [
         <a href="#rid56">
          56,57
         </a>
         ]. Indeed, studies report that only 2 to 12 percent of patients with a solitary kidney require permanent dialysis after partial nephrectomy [
         <a href="#rid55">
          55,58,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2217547016">
         <span class="h3">
          Multiple or bilateral tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 15 percent of patients with papillary tumors and 8 percent of those with other histologic subtypes have multicentric tumors [
         <a href="#rid60">
          60
         </a>
         ]. In addition, between 1 and 4 percent of patients with sporadic tumors have bilateral RCCs [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         For patients who have multiple and/or bilateral tumors, some experts advocate active surveillance and defer intervention until any lesion increases to 3 cm or larger [
         <a href="#rid62">
          62
         </a>
         ]. This size criterion was derived from studies in patients with von Hippel-Lindau disease, in whom preservation of renal parenchyma is critically important because of the high likelihood of additional subsequent renal lesions [
         <a href="#rid63">
          63
         </a>
         ]. If nephrectomy is indicated, we prefer a partial nephrectomy if technically feasible because the goal is to maintain as much renal function as possible without compromising long-term outcomes [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         While most patients with familial RCC have two functional kidneys, they are very likely to experience bilateral tumors, tumor recurrence, and require multiple renal surgeries throughout their lifetime [
         <a href="#rid65">
          65
         </a>
         ].
         <sup>
         </sup>
         As such, for most RCC syndrome patients, it is important to hold off surgery until the tumor(s) are larger than 3 cm and utilize a partial nephrectomy whenever possible [
         <a href="#rid62">
          62
         </a>
         ]. Further discussions of von Hippel-Lindau disease and other hereditary kidney cancer syndromes are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Renal cell carcinomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2885516311">
         <span class="h3">
          Baseline renal dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with preoperative renal dysfunction and those at risk for chronic kidney disease, a partial nephrectomy should be performed when technically feasible in order to preserve renal function. (See
         <a class="local">
          'Partial nephrectomy'
         </a>
         above.)
        </p>
        <p>
         The impact on subsequent renal function after a partial versus radical nephrectomy was evaluated in a study of 662 patients who had a solitary cortical lesion &lt;4 cm, an apparently healthy contralateral kidney, and a baseline serum creatinine less than 1.4 mg/dL [
         <a href="#rid22">
          22
         </a>
         ]. Three years after surgery, patients undergoing partial nephrectomy had a significantly lower likelihood of renal dysfunction than those undergoing radical nephrectomy (5 versus 36 percent, respectively).
        </p>
        <p class="headingAnchor" id="H290798222">
         <span class="h2">
          Techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         During partial nephrectomy, the kidney should be carefully examined to exclude a synchronous tumor. The importance of this was illustrated in a series of 112 patients with sporadic renal masses who underwent partial nephrectomy [
         <a href="#rid66">
          66
         </a>
         ]. A second lesion was identified in 37 cases, and 8 (7 percent of the entire series) were malignant. In addition, conversion to a radical nephrectomy may be necessary based on intraoperative findings. For example, some urologists convert the surgery to radical nephrectomy in cases with renal vein invasion or sarcomatoid histology on frozen section.
        </p>
        <p>
         A formal lymphadenectomy is usually not performed during a partial nephrectomy, as partial nephrectomy is typically performed for smaller tumors with lower incidence of nodal metastasis. For patients who are candidates for a partial nephrectomy, concomitant adrenalectomy is not routinely indicated. This was illustrated in a series of 2065 patients undergoing partial nephrectomy at a single institution, of whom a concomitant adrenalectomy was performed in 48 cases (2 percent) [
         <a href="#rid27">
          27
         </a>
         ]. At final pathology, only 3 of the 48 patients (7 percent) had adrenal invasion or metastasis, and three others had a separate adrenal neoplasm.
        </p>
        <p class="headingAnchor" id="H89702150">
         <span class="h2">
          Significance of margin status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unlike those who undergo a radical nephrectomy, patients who undergo a partial nephrectomy for RCC are at risk that surgery will not completely remove the tumor and that positive margins may be identified at final pathology. A positive surgical margin has been linked with inferior oncologic outcomes, such as a higher recurrence rate, in many studies [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p>
         Whether a frozen section should be performed in these patients is controversial. While a frozen section reduces the risk of a positive margin (and, therefore, leaving tumor behind), the limited data suggest that performing a frozen section does not influence survival outcomes [
         <a href="#rid70">
          70
         </a>
         ]. As such, our approach is to perform a frozen section if an open surgical procedure is done because it allows further tissue resection if necessary and increases the likelihood that the entire tumor has been removed. When these procedures are being done laparoscopically or robotically, the opportunity to resect further tumor is more limited. In those circumstances, a frozen section is not usually performed.
        </p>
        <p>
         There are conflicting data regarding the prognostic implications of and treatment options for a positive final surgical margin, particularly in high-risk patients [
         <a href="#rid71">
          71-73
         </a>
         ]. Given that a positive surgical margin does not necessarily predict recurrence, and that a higher recurrence rate does not necessary predict worse survival in this population [
         <a href="#rid74">
          74,75
         </a>
         ], our approach is to proceed with surveillance following partial nephrectomy in all patients with RCC, regardless of the margin status [
         <a href="#rid76">
          76
         </a>
         ]. Other options would include repeat excision, completion radical nephrectomy, or thermal ablation. However, since local recurrence is uncommon (&lt;10 percent), surveillance is the preferable option for management of the renal primary, with adjuvant immunotherapy considered for control of systemic recurrence in appropriate patients [
         <a href="#rid74">
          74,75
         </a>
         ]. (See
         <a class="local">
          'Post-treatment surveillance'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy for locoregional disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H403726639">
         <span class="h2">
          Enucleation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enucleation refers to the removal of the tumor itself without dissection into the uninvolved renal parenchyma. For RCC, enucleation has been most commonly used in patients with familial RCC, multifocal disease, or severe CKD to optimize parenchymal mass preservation [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         There are no prospective data comparing enucleation with partial nephrectomy. Limited retrospective data suggest it is comparable to surgery as a treatment of small renal lesions [
         <a href="#rid78">
          78,79
         </a>
         ]. Until more data become available, we suggest a partial nephrectomy with excision of the tumor and a rim of normal parenchyma, rather than enucleation.
        </p>
        <p class="headingAnchor" id="H1133245402">
         <span class="h1">
          ALTERNATIVES TO SURGICAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with localized RCC who are not surgical candidates for whatever reason, nonsurgical approaches, including thermal ablation (radiofrequency ablation or cryotherapy) or active surveillance (for tumors &lt;4 cm), are appropriate alternatives. These options are discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/3001.html" rel="external">
          "Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma", section on 'Active surveillance in nonsurgical candidates'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27538209">
         <span class="h1">
          ADJUVANT THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients treated with definitive surgery for RCC, the use of adjuvant therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy for locoregional disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy after metastasectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          POST-TREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal surveillance strategy after potentially curative treatment for RCC has not been well studied. Follow-up should be based upon the individual patient's risk for recurrence. (See
         <a class="medical medical_review" href="/z/d/html/2969.html" rel="external">
          "Surveillance for metastatic disease after definitive treatment for renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3697949475">
         <span class="h1">
          SPECIAL CONSIDERATIONS DURING THE COVID-19 PANDEMIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         The COVID-19 pandemic has increased the complexity of cancer care. Important issues include balancing the risk from delaying cancer treatment versus harm from COVID-19, minimizing the number of clinic and hospital visits to reduce exposure whenever possible, mitigating the negative impacts of social distancing on delivery of care, and appropriately and fairly allocating limited healthcare resources. Specific guidance for decision-making for cancer surgery on a disease-by-disease basis is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facs.org%252Fcovid-19%252Fclinical-guidance%252Felective-case%26data%3D02%7C01%7CCatherine.Zuo%2540wolterskluwer.com%7C6edf35fec8a44aa5ba7e08d7e0abd442%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637224900908106614%26sdata%3DBZ46NEWlwLXBS%252BzuXX2ZECn0eWC5venMMOsQsbx20IU%253D%26reserved%3D0&amp;token=qRRbrus%2FSri1CCXBHEFm1Ig0Jf4oCI5jHTY3%2FI9L63gd4n8nQjiz8Ox53xBOxI8E%2FMGEWS15dXwsFTSZgwDwjK7tpJbBa7NEQzgTLxUtYffdRf%2F4Fc5rByj7%2FkXP%2FXUtHckhQ2Yn9GtqgHGuZSFWqdYkfvdALymVdcy2X3EZD5X5P%2BBfBtl2bm3Cf%2B9ww62XtFXXkI7Z6izXD1ShzwnO0bVvF0kxtVD9QvPzMPFBeink2fubU4mzobC1HeqSTv2vHII21kZGkZ7d%2FHiqD%2F2G1qh%2Frfk3P0SX8xOpV%2FlKqC21nZ0St6YyMu4GuKQ%2BaK4%2FDaOy5jcBYf48DUZwCH9s89Ivjs%2FHIWivzm2R9btOmkQ%3D&amp;TOPIC_ID=2985" target="_blank">
          American College of Surgeons
         </a>
         , from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.surgonc.org%252Fresources%252Fcovid-19-resources%252F%26data%3D02%7C01%7CCatherine.Zuo%2540wolterskluwer.com%7C6edf35fec8a44aa5ba7e08d7e0abd442%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637224900908116601%26sdata%3DpqQAjg%252F2hyLF5UboMZQ0FesSux0UjefT%252B6iDu1TycdY%253D%26reserved%3D0&amp;token=oOFUrQX%2Fyz9anNRKwsCcPypQbsLiACRwFTdqMBOyyCLjPjeuIcEQ1dPOVlN599%2BULH%2FuvVQKW7MZMVoWVWro8%2Fq5j7RI0ZnDY%2BOJjtqybxPVr%2B8Op54WnCF4LRSft%2F16SLu%2Fs2DKSJ5ElPtZYJWQyck25F8QCj%2F4MOUTABo%2BEEl7C8CexDrdaf99f%2FMjfSUcDcBq3KSDaxICfGfxQe5V%2Br61QeIpBSJRmQbFJT%2F8xgmGDzQoIXdLZ9FCfYfQMoYkq9%2BNp%2F0j%2F9nvjbTpQ6Js%2BnWyYDHtUNlN4o2EcvUT3jCXjP7i7YT8SsjaoGm5ZBMZSrf1V6wplIkswVdhZOS%2FwPgzEdu4rvZwnr6uNpk7Kkw%3D&amp;TOPIC_ID=2985" target="_blank">
          Society for Surgical Oncology
         </a>
         , and from others. These and other recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">
          "COVID-19: Considerations in patients with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1139454352">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/888.html" rel="external">
          "Patient education: Renal cell carcinoma (kidney cancer) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for surgery
         </strong>
         – For patients with nonmetastatic renal cell carcinoma (RCC) who are operative candidates, surgical resection is potentially curative (see
         <a class="local">
          'Indications'
         </a>
         above). The role of cytoreductive nephrectomy in other patients with metastatic RCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radical versus partial nephrectomy
         </strong>
         – For patients undergoing definitive surgical treatment for RCC, either a radical or partial nephrectomy may be performed. Our approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Radical versus partial nephrectomy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a primary tumor ≤4 cm, we recommend a partial nephrectomy rather than radical nephrectomy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). In such patients, partial nephrectomy is oncologically equivalent to radical nephrectomy with a lower risk of future renal compromise. (See
         <a class="local">
          'Partial nephrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a primary tumor between 4 and 10 cm, we suggest a partial nephrectomy when it is technically feasible, especially in the presence of a solitary kidney, multiple and/or bilateral renal tumors, familial RCC syndrome, and baseline renal dysfunction (chronic kidney disease [CKD] or proteinuria) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Indications for nephron-preserving surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a primary tumor &gt;10 cm or those involving a more central position of the kidney, we perform a radical nephrectomy. (See
         <a class="local">
          'Radical nephrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Open versus minimally invasive surgery
         </strong>
         – Both radical and partial nephrectomy can be performed as an open surgical procedure or laparoscopically/robotically. The choice of surgical technique should be based on patient- and tumor-specific considerations (eg, tumor location and size) and the technical expertise available. (See
         <a class="local">
          'Open versus minimally invasive approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radical nephrectomy
         </strong>
         – Radical nephrectomy consists of early ligation of the renal artery and vein and removal of the kidney, Gerota fascia, and, on occasion, the ipsilateral adrenal gland. (See
         <a class="local">
          'Radical nephrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lymphadenectomy
         </strong>
         – Patients with RCC should undergo a lymph node dissection at the time of radical nephrectomy. Lymph node dissection for RCC is primarily for staging and prognostic purposes. (See
         <a class="local">
          'Retroperitoneal lymph nodes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with suspected retroperitoneal lymph node involvement and those at high risk for nodal involvement, we perform an extended lymphadenectomy at the time of radical nephrectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients in whom retroperitoneal lymph node involvement is not suspected and those at low risk for nodal involvement, we perform a limited lymph node dissection concentrated around the renal hilum.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cavoatrial tumor involvement
         </strong>
         – For patients with tumor thrombus involvement of the inferior vena cava (IVC) or right atrium but no nodal or distant metastasis, we recommend tumor thrombectomy at the time of radical nephrectomy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Cavoatrial tumor involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adrenal gland involvement
         </strong>
         – Patients with RCC that directly extends to the ipsilateral adrenal gland and those at risk for invasion of the adrenal gland should undergo adrenalectomy at the time of radical nephrectomy. However, adrenalectomy should not be performed if the contralateral adrenal gland is absent and the ipsilateral gland demonstrates normal morphology and no malignant involvement. (See
         <a class="local">
          'Adrenal gland involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial nephrectomy
         </strong>
         – Partial nephrectomy results in similar oncologic outcomes compared with radical nephrectomy in appropriately selected patients. In addition, it is associated with a significantly lower risk of chronic renal dysfunction. (See
         <a class="local">
          'Partial nephrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Margin status
         </strong>
         – For patients undergoing partial nephrectomy, we aim for negative surgical margins. We may obtain frozen section in open cases, where additional resection is feasible, but not minimally invasive cases. We proceed with surveillance for local recurrence following partial nephrectomy in all patients with RCC, regardless of the margin status. A positive surgical margin has been associated with a higher recurrence rate in some studies, but not a worse survival rate. (See
         <a class="local">
          'Significance of margin status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Enucleation
         </strong>
         – For patients undergoing partial nephrectomy, we suggest dissecting the tumor with a margin of surrounding parenchyma rather than enucleation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Enucleation'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol 2021; 206:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scosyrev E, Messing EM, Sylvester R, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014; 65:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierorazio PM, Johnson MH, Patel HD, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol 2016; 196:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ochoa-Arvizo M, García-Campa M, Santos-Santillana KM, et al. Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis. Urol Oncol 2023; 41:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong IG, Khandwala YS, Kim JH, et al. Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015. JAMA 2017; 318:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess NA, Koo BC, Calvert RC, et al. Randomized trial of laparoscopic v open nephrectomy. J Endourol 2007; 21:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombo JR Jr, Haber GP, Jelovsek JE, et al. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology 2008; 71:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger A, Brandina R, Atalla MA, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009; 182:2172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurram S, Kavoussi L. Laparoscopic Partial Nephrectomy. J Endourol 2020; 34:S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter J. Robotic partial nephrectomy: the treatment of choice for minimally invasive nephron-sparing surgery. BJU Int 2015; 116:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benway BM, Bhayani SB, Rogers CG, et al. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes. J Urol 2009; 182:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dev HS, Sooriakumaran P, Stolzenburg JU, Anderson CJ. Is robotic technology facilitating the minimally invasive approach to partial nephrectomy? BJU Int 2012; 109:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Z, Li M, Liu B, et al. Robotic versus open partial nephrectomy: a systematic review and meta-analysis. PLoS One 2014; 9:e94878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia L, Wang X, Xu T, Guzzo TJ. Systematic Review and Meta-Analysis of Comparative Studies Reporting Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Versus Open Partial Nephrectomy. J Endourol 2017; 31:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asimakopoulos AD, Miano R, Annino F, et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol 2014; 14:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crocerossa F, Carbonara U, Cantiello F, et al. Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2021; 80:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leow JJ, Heah NH, Chang SL, et al. Outcomes of Robotic versus Laparoscopic Partial Nephrectomy: an Updated Meta-Analysis of 4,919 Patients. J Urol 2016; 196:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Zhang L, Luo Q, et al. Long-Term Survival and Prognostic Factors After Laparoscopic Radical Nephrectomy. Altern Ther Health Med 2023; 29:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dursun F, Elshabrawy A, Wang H, et al. Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma. Int J Clin Oncol 2022; 27:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeon HG, Choo SH, Sung HH, et al. Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. Eur J Cancer 2014; 50:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HD, Pierorazio PM, Johnson MH, et al. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2017; 12:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell RE, Lee BT, Cookson MS, et al. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Cancer 2009; 115:2447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu RCJ, Salika T, Maw J, et al. Influence of hospital volume on nephrectomy mortality and complications: a systematic review and meta-analysis stratified by surgical type. BMJ Open 2017; 7:e016833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. J Urol 2009; 181:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratslavsky G, Linehan WM. Surgery: Routine adrenalectomy in renal cancer--an antiquated practice. Nat Rev Urol 2011; 8:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013; 64:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall FF, Steinberg GD, Pound CR, Partin AW. Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection. World J Urol 1995; 13:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalapara AA, Frydenberg M. The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Transl Androl Urol 2020; 9:3123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crispen PL, Breau RH, Allmer C, et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 2011; 59:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011; 60:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campi R, Sessa F, Di Maida F, et al. Templates of Lymph Node Dissection for Renal Cell Carcinoma: A Systematic Review of the Literature. Front Surg 2018; 5:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999; 36:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blom JH, van Poppel H, Maréchal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011; 185:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershman B, Thompson RH, Moreira DM, et al. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol 2017; 71:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta V, Mudaliar K, Ghai R, et al. Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. Arch Pathol Lab Med 2013; 137:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaptein FHJ, van der Hulle T, Braken SJE, et al. Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. JACC CardioOncol 2022; 4:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lardas M, Stewart F, Scrimgeour D, et al. Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. Eur Urol 2016; 70:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int 2012; 110:E470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawindy SM, Kurian T, Kim T, et al. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int 2012; 110:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almatari AL, Sathe A, Wideman L, et al. Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist. Urol Oncol 2023; 41:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Y, de Castro Abreu AL, Gill IS. Robotic inferior vena cava thrombus surgery: novel strategies. Curr Opin Urol 2014; 24:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manassero F, Mogorovich A, Di Paola G, et al. Renal cell carcinoma with caval involvement: contemporary strategies of surgical treatment. Urol Oncol 2011; 29:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuch B, Larochelle JC, Onyia T, et al. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol 2009; 181:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005; 48:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weight CJ, Kim SP, Lohse CM, et al. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol 2011; 60:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunn AJ, Patel AR, Rais-Bahrami S. Role of Angio-Embolization for Renal Cell Carcinoma. Curr Urol Rep 2018; 19:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May M, Brookman-Amissah S, Pflanz S, et al. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol 2009; 82:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zargar H, Addison B, McCall J, et al. Renal artery embolization prior to nephrectomy for locally advanced renal cell carcinoma. ANZ J Surg 2014; 84:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLennan S, Imamura M, Lapitan MC, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol 2012; 62:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mashni JW, Assel M, Maschino A, et al. New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. Urology 2015; 86:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasuda Y, Zhang JH, Attawettayanon W, et al. Comprehensive Management of Renal Masses in Solitary Kidneys. Eur Urol Oncol 2023; 6:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen CT, Campbell SC, Novick AC. Choice of operation for clinically localized renal tumor. Urol Clin North Am 2008; 35:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fergany AF, Saad IR, Woo L, Novick AC. Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. J Urol 2006; 175:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghavamian R, Cheville JC, Lohse CM, et al. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol 2002; 168:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKiernan J, Yossepowitch O, Kattan MW, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002; 60:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel MI, Simmons R, Kattan MW, et al. Long-term follow-up of bilateral sporadic renal tumors. Urology 2003; 61:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001; 165:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomella PT, Linehan WM, Ball MW. Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. Genes (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fadahunsi AT, Sanford T, Linehan WM, et al. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol 2011; 185:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol 2013; 23:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raz O, Mendlovic S, Leibovici D, et al. The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery. J Urol 2007; 178:1892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalifeh A, Kaouk JH, Bhayani S, et al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). J Urol 2013; 190:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petros FG, Metcalfe MJ, Yu KJ, et al. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol 2018; 36:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothberg MB, Peak TC, Reynolds CR, Hemal AK. Long-term oncologic outcomes of positive surgical margins following robot-assisted partial nephrectomy. Transl Androl Urol 2020; 9:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venigalla S, Wu G, Miyamoto H. The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases. Clin Genitourin Cancer 2013; 11:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yossepowitch O, Thompson RH, Leibovich BC, et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 2008; 179:2158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol 2010; 57:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah PH, Moreira DM, Okhunov Z, et al. Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors. J Urol 2016; 196:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radfar MH, Ameri F, Dadpour M, et al. Partial nephrectomy and positive surgical margin, oncologic outcomes and predictors: a 15-year single institution experience. Cent European J Urol 2021; 74:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai R, Gao L, Wang J, Jiang Q. Positive surgical margins may not affect the survival of patients with renal cell carcinoma after partial nephrectomy: A meta-analysis based on 39 studies. Front Oncol 2022; 12:945166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bansal RK, Tanguay S, Finelli A, et al. Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. Can Urol Assoc J 2017; 11:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García AG, León TG. Simple Enucleation for Renal Tumors: Indications, Techniques, and Results. Curr Urol Rep 2016; 17:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carini M, Minervini A, Masieri L, et al. Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 2006; 50:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minervini A, Tuccio A, Masieri L, et al. Endoscopic robot-assisted simple enucleation (ERASE) for clinical T1 renal masses: description of the technique and early postoperative results. Surg Endosc 2015; 29:1241.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2985 Version 42.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cancer statistics, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34115547" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21186077" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23850254" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27157369" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36642639" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067427" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17638555" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Randomized trial of laparoscopic v open nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18313111" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19758651" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459148" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Laparoscopic Partial Nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26260420" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Robotic partial nephrectomy: the treatment of choice for minimally invasive nephron-sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19616229" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21939489" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Is robotic technology facilitating the minimally invasive approach to partial nephrectomy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24740259" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Robotic versus open partial nephrectomy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27305835" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Systematic Review and Meta-Analysis of Comparative Studies Reporting Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Versus Open Partial Nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25234265" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Robotic radical nephrectomy for renal cell carcinoma: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33218826" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27291654" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Outcomes of Robotic versus Laparoscopic Partial Nephrectomy: an Updated Meta-Analysis of 4,919 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36350322" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Long-Term Survival and Prognostic Factors After Laparoscopic Radical Nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35319076" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16945768" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24060356" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483780" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19309750" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28877947" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Influence of hospital volume on nephrectomy mortality and complications: a systematic review and meta-analysis stratified by surgical type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19371896" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Management of the adrenal gland during partial nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931345" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Surgery: Routine adrenalectomy in renal cancer--an antiquated practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23643550" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7550387" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33457285" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The role of open radical nephrectomy in contemporary management of renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20933322" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940096" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lymph node dissection in renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30619877" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Templates of Lymph Node Dissection for Renal Cell Carcinoma: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10559610" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18848382" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21419453" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27671144" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23651149" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36444235" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26707869" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22519938" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22540179" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36804205" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24451090" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Robotic inferior vena cava thrombus surgery: novel strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19963407" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Renal cell carcinoma with caval involvement: contemporary strategies of surgical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19110280" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936136" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514718" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30091047" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Role of Angio-Embolization for Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255117" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24548680" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Renal artery embolization prior to nephrectomy for locally advanced renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22841673" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26362947" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36517406" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comprehensive Management of Renal Masses in Solitary Kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435813" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nephron sparing surgery for renal tumors: indications, techniques and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18992618" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Choice of operation for clinically localized renal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16600716" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12131287" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475658" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12736005" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-term follow-up of bilateral sporadic renal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176466" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33670168" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21074206" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22705279" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The metabolic basis of kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17868730" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23764077" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29488096" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32420203" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Long-term oncologic outcomes of positive surgical margins following robot-assisted partial nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23871293" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18423758" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19359089" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26907508" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35083070" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Partial nephrectomy and positive surgical margin, oncologic outcomes and predictors: a 15-year single institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36033492" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Positive surgical margins may not affect the survival of patients with renal cell carcinoma after partial nephrectomy: A meta-analysis based on 39 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28652876" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26728315" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Simple Enucleation for Renal Tumors: Indications, Techniques, and Results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16787695" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25159647" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Endoscopic robot-assisted simple enucleation (ERASE) for clinical T1 renal masses: description of the technique and early postoperative results.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
